Journal
TARGETED ONCOLOGY
Volume 11, Issue 2, Pages 235-238Publisher
SPRINGER
DOI: 10.1007/s11523-015-0384-7
Keywords
-
Categories
Funding
- Russian Scientific Fund [14-15-00528]
- Russian Science Foundation [14-15-00528] Funding Source: Russian Science Foundation
Ask authors/readers for more resources
Vemurafenib, a specific inhibitor of mutated BRAF kinase, may activate wild-type BRAF and therefore induce squamous cell skin carcinomas in patients treated for melanoma. All vemurafenib clinical trials excluded patients with multiple primary malignant tumors; therefore, the action of this drug on concurrent BRAF wild-type malignancies remains insufficiently studied. We observed a patient, who was administered vemurafenib for BRAF mutation-containing melanoma, but experienced immediate relapse of previously controlled breast cancer disease. Interestingly, breast cancer lesions underwent regression soon after vemurafenib discontinuation. Therefore, caution must be taken while considering vemurafenib treatment for patients with multiple tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available